You're right but I guess the saving grace of the situation is that when the data is compiled and becomes public and is favorable it would quickly become known to neurologists and wouldn't need to be advertised.
Similarly, I think it's favorable that drug companies don't have a vested interest in Cyclophosphamide (Cytoxan) because the concept of "rebooting" is the interesting thing and not the drug itself. Cyclophosphamide itself is nothing more than the far from perfect first step which hopefully new agents will be invented/perfected along the way until we end up with what Tovaxin was represented to be.....eliminating only the abberant cells responsible for the MS process.
So really what is (hopefully) going on is that, because we don't know which part(s) of the immune system are responsible for MS, Cyclophosphamide is used to kill the whole immune system with the hopes that the new immune system is naive to MS and hopefully with time the evolution of what started as a "sledgehammer" approach will result in a treatment that is very specific and refined.
Of course all that is of little value to people who are convinced that immune system involvement is secondary.
Proper data for docs can't be compiled for neurologists because that would require extensive Phase III trials and we know that won't happen under the current situation.
And we now come to the next point which the two of us have agreed to disagree in the past...and that is the immune system "causes" MS. Some MS researchers believe that while the immune system attacks on the inflammation involved around myelin is an additional problem, that is not what causes the MS in the first place. The immune system is simply reacting to inflammation. They feel there is another process that initiates the inflammation. Neither side of the fence has been able to prove their theories and as a result, the cause and anything resembling a viable treatment still isn't within reach. I won't even count the number of times I've heard "the answer is just around the corner."
So in the meantime, the drug companies will continue to develop very powerful and expensive immune system altering drugs to treat MS and the patients will continue to have the disease progress, albeit at various rates and severity levels.